Products & Reviews

In 1997, a group of prominent pharmaceutical companies came together in the form of a consortium with the express intent of developing a new impactor specifically for inhaled and nasal products. The result, the Next Generation Impactor (NGI), was launched in 2000 and subsequently accepted into the Pharmacopoeias in 2005. The NGI has seven stages, five of which are in the range 0.5 to 5 microns plus a micro-orifice collector w…